Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.

Authors

David Miles

Mt Vernon Cancer Centre, London, United Kingdom

David Miles , Andrea Lacasia , Luen Lee , Kenneth Dana , Sarah Heeson , Adam Knott , Chia C. Portera , Sandra M. Swain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

First Author: Sandra M. Swain

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study.

First Author: Michael Ewer

insert_chart_outlined

Poster

2023 ASCO Breakthrough

bookmark_border

Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.

First Author: WanChen Hsieh

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.

First Author: Nicholas Patrick McAndrew